USSTOCK.TODAY
Market Closed
Log in Sign up

MetaVia Inc(MTVA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today

MTVA
MTVA
MetaVia Inc
At close Nov 19 at 4:00 PM ET (Korea 11/20 06:00)
$1.07
+0.01 ▲ +0.94%
Nov 19 at 7:16 PM ET (Korea 11/20 09:16)
$1.07
+0.00 +0.00%

Full metrics table

Index ⓘ -P/E ⓘ -EPS (ttm) ⓘ -3.21Insider Own ⓘ 28.08%Shs Outstand ⓘ 6.7MPerf Week ⓘ -17.69%
Market Cap ⓘ 0.01BForward P/E ⓘ -EPS next Y ⓘ 17.63%Insider Trans ⓘ -Shs Float ⓘ 4.8MPerf Month ⓘ -20.15%
Enterprise Value ⓘ -0.00BPEG ⓘ -EPS next Q ⓘ -0.79Inst Own ⓘ 3.35%Short Float ⓘ 1.16%Perf Quarter ⓘ -26.71%
Income ⓘ -0.02BP/S ⓘ -EPS this Y ⓘ 63.22%Inst Trans ⓘ 3.63%Short Ratio ⓘ 0.49Perf Half Y ⓘ -62.72%
Sales ⓘ 0.00BP/B ⓘ 2.99EPS next 5Y ⓘ 39.97%ROA ⓘ -129.05%Short Interest ⓘ 0.06MPerf YTD ⓘ -87.29%
Book/sh ⓘ 0.36P/C ⓘ 0.82EPS past 3/5Y ⓘ 75.13% 72.69%ROE ⓘ -359%52W High ⓘ -92.03% ($13.42)Perf Year ⓘ -87.27%
Cash/sh ⓘ 1.3P/FCF ⓘ -Sales past 3/5Y ⓘ -ROIC ⓘ -629.19%52W Low ⓘ 10.75% ($0.97)Perf 3Y ⓘ -97.23%
Dividend Est. ⓘ -EV/EBITDA ⓘ -EPS Y/Y TTM ⓘ 78.48%Gross Margin ⓘ -Volatility(W/M) ⓘ 13.89% 14.78%Perf 5Y ⓘ -99.97%
Dividend TTM ⓘ -EV/Sales ⓘ -Sales Y/Y TTM ⓘ -Oper. Margin ⓘ -ATR (14) ⓘ 0.17Perf 10Y ⓘ -100%
Dividend Ex-Date ⓘ -Quick Ratio ⓘ 1.28EPS Q/Q ⓘ 54.51%Profit Margin ⓘ -RSI (14) ⓘ 39.97Recom ⓘ 1
Dividend Gr. 3/5Y ⓘ -Current Ratio ⓘ 1.28Sales Q/Q ⓘ -SMA20 ⓘ -15.11% ($1.26)Beta ⓘ 1.21Target Price ⓘ $17.67
Payout ⓘ -Debt/Eq ⓘ 0.07Earnings ⓘ 2026/11/13SMA50 ⓘ -24.15% ($1.41)Rel Volume ⓘ 0.52Prev Close ⓘ $1.06
Employees ⓘ 8LT Debt/Eq ⓘ 0.03EPS/Sales Surpr. ⓘ 5.9% -SMA200 ⓘ -32.46% ($1.58)Avg Volume(3M) ⓘ 0.11MPrice ⓘ $1.07
IPO ⓘ 2016/8/5Option/Short ⓘ No/YesTrades ⓘ 447Volume ⓘ 59,163Change ⓘ 0.94%
Company
MTVA MTVAMetaVia Inc | NASD | Biotechnology Deep dive

💉 This is a clinical-stage biotech developing next-generation GLP-1 class drugs targeting obesity and metabolic diseases. Its lead pipeline candidate, DA-1726, is a dual-agonist that simultaneously activates the GLP-1 and glucagon receptors for obesity treatment, while its follow-on asset, DA-1241 (vanogliflozin), targets metabolic liver disease (MASH). It is a nano-cap company listed on the Nasdaq.

Quote

Over the past 1 year, on the lower side

92% below its 1-year high.

Now $1.07
52w low$0.9752w high$13.42
52W Range1%
Volume ⓘ 59,163

Traded less than usual. That is 52% of its average volume.

C
Overall · average, with some caution
We judged 6 of the 8 questions below. 1 rate excellent and 2 need caution.
No data for valuation, dividends, or not applicable.
Peer comparison Biotechnology

It ranks #515 of 598 in the industry

Based on market cap of $7M.

FAQ

FAQ

What kind of company is MTVA?

MTVA belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of MTVA?

The market cap of MTVA is approximately $7M, ranking 5,459 within its sector.

What is the 52-week high and low for MTVA?

MTVA has recorded a 52-week high of $13.42 and a low of $0.97.

Telegram KakaoTalk
Briefs · earnings · signals, first Telegram · KakaoTalk channels